In Türkiye, cangrelor use in adult patients undergoing PCI who have not received oral P2Y12 inhibitors and in whom oral P2Y12 therapy is not feasible or desirable is prescribed based on the Ministry of Health regulations, which have limited its use to patients with cardiogenic shock or cardiac arrest who are unconscious or intubated or cannot be fitted with a nasogastric tube [13]. This evidence concerns the gene P2RY12 and cardiac arrest.